MOESM3 of Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition

Additional file 3: Fig S3. Vemurafenib has minimal negative effect on gp100-specific T cell priming. pDCs and mDCs from a HLA-A2.1 + donor were loaded with different concentrations of a melanoma-specific peptide (gp100280:288) or irrelevant peptide (tyrosinase369:376) in the presence of R848 with/without vemurafenib and gp100280:288 specific T cells. Graphs show the cell surface expression levels of CD25 after overnight co-culture. Shown is the mean (+SEM) of three independent experiments